Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 367

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

Open access
Koh, Yasuhiro, Nakata, Hirotomo, Maeda, Kenji, Ogata, Hiromi, Bilcer, Geoffrey, Devasamudram, Thippeswamy, Kincaid, John F., Boross, Peter, Wang, Yuan-Fang, Tie, Yunfeng, Volarath, Patra, Gaddis, Laquasha, Harrison, Robert W., Weber, Irene T., Ghosh, Arun K., Mitsuya, Hiroaki · 2003 · Antimicrobial Agents and Chemotherapy

Abstract

We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3( R ),3a( S ),6a( R )- bis -tetrahydrofuranylurethane ( bis -THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC 50 ], ∼0.003 μM; IC 90 , ∼0.009 μM) with minimal cytotoxicity (50% cytotoxic concentration for CD4 + MT-2 cells, 74 μM). UIC-94017 blocked the infectivity and replication of each of HIV-1 NL4-3 variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 μM (IC 50 s, 0.003 to 0.029 μM), although it was less active against HIV-1 NL4-3 variants selected for resistance to amprenavir (IC 50 , 0.22 μM). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.47.10.3123-3129.2003

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 367

Metadata

Authors
Koh, Y., Nakata, H., Maeda, K., Ogata, H., Bilcer, G., Devasamudram, T., Kincaid, J. F., Boross, P., Wang, Y.-F., Tie, Y., Volarath, P., Gaddis, L., Harrison, R. W., Weber, I. T., Ghosh, A. K., & Mitsuya, H.
Venue
Antimicrobial Agents and Chemotherapy
Published
2003-10
Volume
47
Issue
10
Pages
3123-3129
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2118245054
Cited by
367
References
22
FWCI
5.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. https://app.cochat.ai/papers/10.1128/aac.47.10.3123-3129.2003
The paper
Koh, Y., Nakata, H., Maeda, K., Ogata, H., Bilcer, G., Devasamudram, T., Kincaid, J. F., Boross, P., Wang, Y.-F., Tie, Y., Volarath, P., Gaddis, L., Harrison, R. W., Weber, I. T., Ghosh, A. K., & Mitsuya, H. (2003). Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.10.3123-3129.2003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.